Lumexa Imaging (NASDAQ:LMRI) Research Coverage Started at Truist Financial

Truist Financial began coverage on shares of Lumexa Imaging (NASDAQ:LMRI) in a report released on Monday, MarketBeat.com reports. The brokerage issued a buy rating and a $18.00 price target on the stock.

A number of other research analysts have also recently weighed in on LMRI. KeyCorp initiated coverage on shares of Lumexa Imaging in a research report on Thursday, September 24th. They set an “overweight” rating and a $18.00 price objective on the stock. Deutsche Bank Aktiengesellschaft set a $16.00 target price on shares of Lumexa Imaging in a report on Thursday, August 13th. Wall Street Zen raised shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Raymond James Financial set a $17.00 price objective on shares of Lumexa Imaging in a research report on Monday, September 28th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Lumexa Imaging in a research note on Tuesday, September 22nd. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $16.40.

Lumexa Imaging Price Performance

NASDAQ:LMRI opened at $10.59 on Monday. The firm has a market capitalization of $1.02 billion and a price-to-earnings ratio of -21.61. Lumexa Imaging has a 1 year low of $6.45 and a 1 year high of $19.45. The business has a 50 day simple moving average of $11.29 and a 200-day simple moving average of $10.24. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44.

Lumexa Imaging (NASDAQ:LMRI) last released its earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.17. The company had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Equities analysts forecast that Lumexa Imaging will post 0.25 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in LMRI. Strs Ohio purchased a new stake in shares of Lumexa Imaging during the 1st quarter worth $38,000. PNC Financial Services Group Inc. purchased a new position in Lumexa Imaging in the first quarter valued at about $63,000. State of Wyoming purchased a new position in Lumexa Imaging in the first quarter valued at about $91,000. AXQ Capital LP bought a new position in Lumexa Imaging in the second quarter worth about $128,000. Finally, Bank of America Corp DE purchased a new stake in shares of Lumexa Imaging during the second quarter valued at about $200,000.

About Lumexa Imaging

Lumexa Imaging, Inc (NASDAQ: LMRI) is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company’s operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.